Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI106413

The in vitro inhibition of insulin secretion by diphenylhydantoin

J. Stephen Kizer, Mario Vargas-Cordon, Klaus Brendel, and Rubin Bressler

Department of Medicine, Duke University Medical Center, Durham, North Carolina 27706

Department of Physiology and Pharmacology, Duke University Medical Center, Durham, North Carolina 27706

Find articles by Kizer, J. in: JCI | PubMed | Google Scholar

Department of Medicine, Duke University Medical Center, Durham, North Carolina 27706

Department of Physiology and Pharmacology, Duke University Medical Center, Durham, North Carolina 27706

Find articles by Vargas-Cordon, M. in: JCI | PubMed | Google Scholar

Department of Medicine, Duke University Medical Center, Durham, North Carolina 27706

Department of Physiology and Pharmacology, Duke University Medical Center, Durham, North Carolina 27706

Find articles by Brendel, K. in: JCI | PubMed | Google Scholar

Department of Medicine, Duke University Medical Center, Durham, North Carolina 27706

Department of Physiology and Pharmacology, Duke University Medical Center, Durham, North Carolina 27706

Find articles by Bressler, R. in: JCI | PubMed | Google Scholar

Published October 1, 1970 - More info

Published in Volume 49, Issue 10 on October 1, 1970
J Clin Invest. 1970;49(10):1942–1948. https://doi.org/10.1172/JCI106413.
© 1970 The American Society for Clinical Investigation
Published October 1, 1970 - Version history
View PDF
Abstract

Glucose intolerance has been observed following diphenylhydantoin (DPH) intoxication. Because of this association between DPH and hyperglycemia, the effect of DPH on insulin release in vitro using preparations of isolated islets of Langerhans and pancreatic pieces was examined. In concentrations identical with those considered necessary for adequate anticonvulsant therapy in man, DPH markedly decreases the insulin secretory response of pancreatic pieces to methacholine, 1 μg/ml, tolbutamide, 250 μg/ml, and glucose, 200 mg/100 ml, without any demonstrable alteration in the oxidative conversion of glucose-1-14C or glucose-6-14C to 14CO2 by isolated islets. This DPH-induced inhibition of insulin secretion is not reversed by higher concentrations of glucose (600 mg/100 ml) or by increasing concentrations of extracellular calcium ion (4-6 mmoles/liter). 0.1 mM potassium and 10-4 M ouabain, however, effectively restore the DPH-induced block of insulin secretion in pancreatic pieces. 60 mM potassium ion, on the other hand, not only restores the insulin secretory response to glucose (200 mg/100 ml) but results in an added stimulation of insulin secretion in the presence of DPH. In the presence of DPH, 22Na accumulation by isolated islets is decreased by 26-40% as compared with controls. Such evidence is considered to indirectly support the postulate that the electrophysiological properties of DPH on the pancreas are due to a stimulation of the membrane sodium-potassium-magnesium ATPase.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1942
page 1942
icon of scanned page 1943
page 1943
icon of scanned page 1944
page 1944
icon of scanned page 1945
page 1945
icon of scanned page 1946
page 1946
icon of scanned page 1947
page 1947
icon of scanned page 1948
page 1948
Version history
  • Version 1 (October 1, 1970): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts